Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Combination of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma

NCT01034553 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01034553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01034553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Combination of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2010
Completion date
November 30, 2014
Enrollment
26 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma